Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX)‘s stock had its “buy” rating reiterated by equities research analysts at Jefferies Group LLC in a research note issued on Thursday. They presently have a $59.00 target price on the stock. Jefferies Group LLC’s price objective would suggest a potential upside of 62.09% from the stock’s current price.

PCRX has been the subject of several other research reports. Canaccord Genuity reduced their price objective on shares of Pacira Pharmaceuticals from $56.00 to $48.00 and set a “buy” rating for the company in a research note on Tuesday, August 29th. Mizuho reaffirmed a “buy” rating and set a $54.00 price objective on shares of Pacira Pharmaceuticals in a research note on Wednesday, July 26th. Royal Bank Of Canada set a $58.00 price objective on shares of Pacira Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, July 30th. Cowen and Company reaffirmed a “hold” rating on shares of Pacira Pharmaceuticals in a research note on Wednesday, August 2nd. Finally, Wedbush reaffirmed an “outperform” rating and set a $87.00 price objective on shares of Pacira Pharmaceuticals in a research note on Wednesday, July 19th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and nine have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $52.92.

Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) traded down 2.02% during mid-day trading on Thursday, hitting $36.40. 346,060 shares of the stock were exchanged. Pacira Pharmaceuticals has a 52 week low of $29.95 and a 52 week high of $58.95. The stock’s 50-day moving average is $38.74 and its 200-day moving average is $44.82. The stock’s market capitalization is $1.47 billion.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings data on Wednesday, August 2nd. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.06. The firm had revenue of $70.90 million for the quarter, compared to analysts’ expectations of $73.37 million. Pacira Pharmaceuticals had a negative net margin of 23.36% and a negative return on equity of 12.44%. Pacira Pharmaceuticals’s revenue was up 1.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.21 EPS. Analysts forecast that Pacira Pharmaceuticals will post ($0.17) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/07/pacira-pharmaceuticals-inc-pcrx-receives-buy-rating-from-jefferies-group-llc.html.

In other news, Director Paul J. Hastings sold 1,044 shares of the business’s stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $36.15, for a total value of $37,740.60. Following the completion of the sale, the director now directly owns 3,518 shares in the company, valued at approximately $127,175.70. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO David M. Stack sold 28,885 shares of the business’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $36.37, for a total transaction of $1,050,547.45. Following the completion of the sale, the chief executive officer now owns 159,164 shares of the company’s stock, valued at $5,788,794.68. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 33,390 shares of company stock valued at $1,215,480. Company insiders own 6.60% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in PCRX. BlackRock Inc. lifted its holdings in shares of Pacira Pharmaceuticals by 28,922.7% in the 1st quarter. BlackRock Inc. now owns 3,183,787 shares of the company’s stock worth $145,180,000 after acquiring an additional 3,172,817 shares during the last quarter. HealthCor Management L.P. lifted its holdings in shares of Pacira Pharmaceuticals by 63.1% in the 2nd quarter. HealthCor Management L.P. now owns 1,793,799 shares of the company’s stock worth $85,564,000 after acquiring an additional 693,799 shares during the last quarter. Tudor Investment Corp ET AL bought a new stake in shares of Pacira Pharmaceuticals in the 1st quarter worth approximately $22,867,000. Eaton Vance Management bought a new stake in shares of Pacira Pharmaceuticals in the 2nd quarter worth approximately $19,519,000. Finally, Russell Investments Group Ltd. lifted its holdings in shares of Pacira Pharmaceuticals by 3,599.8% in the 2nd quarter. Russell Investments Group Ltd. now owns 283,513 shares of the company’s stock worth $13,524,000 after acquiring an additional 275,850 shares during the last quarter.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.